Detalhe da pesquisa
1.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med
; 390(4): 326-337, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078508
2.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(5): 535-552, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142374
3.
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Br J Haematol
; 202(1): 48-53, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951278
4.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Br J Haematol
; 194(2): 365-377, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33959947
5.
Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia.
Haematologica
; 109(5): 1566-1569, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268485
6.
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Br J Haematol
; 203(4): 499-500, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696766
7.
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
Haematologica
; 108(3): 882-888, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300776
8.
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Ther Adv Hematol
; 14: 20406207231173489, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273420